RedHill Biopharma (RDHL) Cash from Investing Activities (2012 - 2022)

RedHill Biopharma (RDHL) has reported Cash from Investing Activities for 11 consecutive years, with -$22000.0 the latest figure, recorded in Q3 2022.

• On a quarterly basis, Cash from Investing Activities rose 99.74% year-over-year to -$22000.0 in Q3 2022; TTM through Dec 2022 was $8.3 million, a 201.99% increase from a year earlier, with the FY2025 full-year figure at $1.7 million, up 18944.44% from the prior year.
• Cash from Investing Activities was -$22000.0 for Q3 2022 at RedHill Biopharma, up from -$163000.0 in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $11.7 million in Q3 2019 and troughed at -$49.8 million in Q2 2020.
• A 5-year average of -$1.4 million and a median of $387000.0 in 2021 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities sank 2897.71% in 2019 and soared 2093.02% in 2022, its largest moves.
• Over 5 years, Cash from Investing Activities stood at $175000.0 in 2018, then slumped by 2897.71% to -$4.9 million in 2019, then soared by 260.36% to $7.9 million in 2020, then sank by 55.46% to $3.5 million in 2021, then sank by 100.63% to -$22000.0 in 2022.
• The last three Cash from Investing Activities figures came in at -$22000.0 (Q3 2022), -$163000.0 (Q2 2022), and $8.5 million (Q1 2022), per Business Quant data.